The current and future state of drug price transparency: What life sciences companies need to know

Due to the absence of federal oversight, several states have enacted drug pricing transparency laws to help lower the cost of prescription drugs. With more states continuing to adopt similar forms of legislation, life sciences organizations must understand the changing legal landscape and the implications their business faces now, and in the future.

Listen to Baker Tilly’s informative discussion about the current state and trajectory of future drug price transparency laws, including:

• Which states currently have price transparency laws
• What companies should do now to comply with existing reporting obligations
• How the evolution and adoption of spend transparency laws (e.g., Physician Payments Sunshine Act) can help forecast the outlook of what price transparency laws will look like on the national and international levels

For more information on this topic, or to learn how Baker Tilly’s Value Architects™ can help, contact our team.